Signal
Moderna r&d spend falls nearly a third as phase 3 respiratory trials wind down
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-13 15:31 UTCUpdated 2026-02-13 16:31 UTC
rss
rd_spendclinical_trialsrespiratorymrna
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Fierce Biotech and Fierce Pharma report that Moderna’s R&D spending fell by nearly a third last year, with the company attributing the decline in part to the wind-down of major Phase 3 respiratory trials.
Entities
Moderna
Score total
0.7
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
50%
Why now
- Trade press flagged the year-over-year R&D spend change
- Both outlets link the decline to Phase 3 respiratory trial wind-downs
- Duplicate coverage suggests broad attention to the update
Why it matters
- R&D spend often tracks late-stage trial cadence and program transitions
- Phase 3 wind-downs can signal near-term shifts in clinical execution focus
- Budget changes may affect timing/scale of future clinical work
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- Moderna’s R&D spending fell by nearly a third last year.
- The decline was attributed in part to the wind-down of major Phase 3 respiratory trials.
How sources frame it
- Fierce Biotech: neutral
- Fierce Pharma: neutral
Two near-identical trade writeups; limited detail beyond the R&D spend decline and cited driver.
All evidence
All evidence
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
Fierce Biotech · fiercebiotech.com · 2026-02-13 15:31 UTC
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
Fierce Pharma (All) · fiercepharma.com · 2026-02-13 16:31 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- fiercepharma.com (1)